N/A
Completed N=1,184
Drug Use Investigation of Kaletra
Source: ClinicalTrials.gov NCT01076972 ↗Enrolled (actual)
1,184
Serious AEs
16.0%
Results posted
Mar 2012
Primary outcomePrimary: Total Number of Patients With Adverse Drug Reactions — 649; 67; 211; 130 participants
Summary
This non-interventional, post-marketing observational study was conducted to obtain data, such as safety and effectiveness, from the use of lopinavir/ritonavir (Kaletra) in clinical practice and investigate the necessity to conduct a follow-up post-marketing clinical study in Japan.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Number of Patients With Adverse Drug Reactions |
649; 67; 211; 130; 72; 99 | — |
| PRIMARY Cluster of Differentiation 4 Lymphocyte Count (CD4) |
125.0; 290.6; 257.2; 342.9; 275.9; 366.4 | — |
| PRIMARY Mean Number of Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) Copies Per Milliliter (mL) Using a Logarithmic (Base 10) Transformation at Each Visit |
4.9; 3.5; 2.7; 2.8; 2.7; 2.8 | — |
| PRIMARY Number of Patients Included in Each Center for Disease Control and Prevention (CDC) Classification Category for HIV-infected Adults and Adolescents |
206; 0; 0; 0; 103; 2 | — |
Eligibility Criteria
Inclusion Criteria
- All patients prescribed Kaletra for the treatment of HIV are eligible for this survey.
Exclusion Criteria
- Contraindications according to the Package Insert:
- Patients with a history of hypersensitivity to any ingredient of Kaletra
- Patients who are receiving pimozide, cisapride, ergotamine tartrate, dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate, midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol
Data sourced from ClinicalTrials.gov (NCT01076972). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.